Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey

Alesia Sadosky¹
Caroline Schaefer²
Rachael Mann³
Felicia Bergstrom²
Rebecca Baik²
Bruce Parsons¹
Srinivas Nalamachu⁴
Edward Nieshoff⁵
Brett R Stacey⁶
Alan Anschel⁷
Michael Tuchman⁸

¹Pfizer Inc, New York, NY,
²Covance Market Access Services Inc, Gaithersburg, MD,
³Covance Market Access Services Inc, San Diego, CA,
⁴International Clinical Research Institute, Overland Park, KS,
⁵Rehabilitation Institute of Michigan/Wayne State University, Detroit, MI,
⁶Oregon Health and Science University, Portland, OR,
⁷Rehabilitation Institute of Chicago, Chicago, IL,
⁸Palm Beach Neurological Center, Palm Beach Gardens, FL, USA

Background: The purpose of this study was to characterize the burden of illness among adult subjects with painful diabetic peripheral neuropathy (pDPN) seeking treatment in the US.

Methods: This observational study recruited 112 subjects with pDPN during routine visits from general practitioner and specialist sites. Subjects completed a one-time questionnaire, which included demographics, symptom duration, health care resource use, out-of-pocket costs, employment status, and validated measures that assessed pain, functioning, sleep, anxiety and depression, health status, and productivity. Investigators completed a case report form based on a 6-month retrospective chart review to capture clinical information, pDPN-related treatments, and other pDPN-related health care resource use over the past 6 months. Annualized costs were extrapolated based on reported 6-month health care resource use.

Results: The mean age of the subjects was 61.1 years, 52.7% were female, and 17.9% were in paid employment. The most common comorbid conditions were sleep disturbance/insomnia (43.8%), depressive symptoms (41.1%), and anxiety (35.7%). The mean pain severity score was 5.2 (0–10 scale), and 79.5% reported moderate or severe pain. The mean pain interference with function score was 5.0 (0–10 scale) overall, with 2.0 among mild, 5.1 among moderate, and 7.0 among severe. The mean Medical Outcomes Study sleep problems index score was 48.5 (0–100 scale). The mean health state utility score was 0.61. Among subjects employed for pay, mean overall work impairment was 43.6%. Across all subjects, mean overall activity impairment was 52.3%. In total, 81.3% were prescribed at least one medication for their pDPN; 50.9% reported taking at least one nonprescription medication. Adjusted mean annualized total direct and indirect costs per subject were $4841 and $9730, respectively. Outcomes related to pain interference with function, sleep, health status, activity impairment, prescription medication use, and direct and indirect costs were significantly worse among subjects with more severe pain (P < 0.0020).

Conclusion: Subjects with pDPN exhibited high pain levels, which were associated with poor sleep, function, and productivity. Health care resource utilization in pDPN was prevalent and costs increased with greater pain severity. The burden of pDPN was greater among subjects with greater pain severity.

Keywords: painful diabetic peripheral neuropathy, pain assessment, burden of illness, quality of life, treatment patterns, health care resource use, costs, productivity

Introduction

Painful diabetic peripheral neuropathy (pDPN) is the most common of the diabetic neuropathies, a family of nerve disorders caused by diabetes mellitus, and is also known as distal symmetric sensorimotor polyneuropathy.¹ In the US, an estimated 15% to 30%...
of people with diabetes have pDPN. Further, it is generally believed that pDPN will continue to increase due to aging of the population and higher survival rates from diseases that are associated with neuropathic pain, including diabetes.

Although there are characteristic symptoms associated with neuropathic pain across all subtypes, the most frequent location of pDPN is the lower extremities, particularly in the leg or foot. The most frequent pain pattern reported by patients with pDPN is persistent pain with slight fluctuations. Patients with pDPNs also frequently report that their pain has a radiating quality. Previous research suggests that patients with pDPN have higher rates of anxiety disorders and lower rates of optimal sleep compared with other types of neuropathic pain, such as post-herpetic neuropathy. pDPN can be severe, chronic, and disabling, leading to substantial functional, psychological, and social limitations, particularly with increasing pDPN severity.

In the US, several studies have evaluated the impact of pDPN on patient-reported outcomes. Previous studies have shown that pDPN is associated with substantial humanistic burden based on the following validated patient-reported outcome measures: Brief Pain Inventory-Short Form (BPI-SF), Hospital Anxiety and Depression Scale (HADS), Medical Outcomes Study (MOS) Sleep Scale, 12-item Short-Form Health Survey (SF-12v2), and EuroQol 5-dimensions, 3-levels (EQ-5D-3 L). The negative impact of pDPN on patient-reported outcomes is greater in subjects with more severe pain. The patient-reported burden of pDPN by pain severity has also been demonstrated in a number of European studies. One European study of pDPN reported substantial pain severity and pain-related interference.

Several US studies have also assessed the health care resource utilization and costs associated with pDPN. Compared with controls, patients with pDPNs have a higher rate of health care resource utilization and costs associated with diagnostic procedures, prescriptions, and interventional treatments. In one study, patients with pDPN had consistently higher health care resource utilization and costs across categories of care, including hospital admissions. The same study reported that excess costs associated with pDPN were approximately $6000 annually. Another study demonstrated that pDPN-related pain severity was significantly associated with higher rates of absenteeism and presenteeism, leading to higher indirect costs.

The objective of this study was to characterize recent trends in subjects with pDPN with respect to the following: sociodemographic and clinical characteristics; the impact of pDPN on anxiety, depression, sleep, and health status; current treatment patterns and health care resource utilization; costs to payers and subjects; and indirect costs due to lost productivity. This study adds to the published literature by combining clinical assessment, patient self-reporting on disease impact, health care resource utilization, and productivity loss in one holistic assessment of the patients with pDPN. All analyses have been performed by pain severity.

**Materials and methods**

This cross-sectional, observational study recruited a convenience sample of subjects with pDPN between September 30, 2011 and December 9, 2011 from 20 community-based physician practices across the US, including seven general practitioners/primary care physicians, five neurologists, three pain specialists, three endocrinologists, as well as one podiatrist and one rheumatologist. The study was approved by a central institutional review board (Concordia Clinical Research, Cedar Knolls, NJ, USA).

Sites were asked to identify eligible subjects with pDPN as they presented for routine office visits. Adult subjects (>18 years) diagnosed with pDPN, defined as subjects with diabetic distal symmetrical sensorimotor polyneuropathy (peripheral neuropathy), at least 6 months earlier who also were managed at the physician’s practice for at least 6 months were eligible for enrollment. Subjects were also required to read and understand English and must have experienced symptoms due to neuropathy for at least 3 months prior to enrollment. Subjects were not eligible for enrollment if: they had participated in an investigational drug study in the 6 months prior to enrollment; had a serious or unstable medical or psychological condition that, in the opinion of the physician, would compromise participation in the study; or had a concomitant illness unrelated to pDPN that may confound the assessment of pDPN (ie, fracture, lupus, rheumatoid arthritis).

Subjects were asked to complete a self-administered questionnaire, which included questions related to demographics, symptom duration, nonprescription treatments, out-of-pocket costs (in the past 4 weeks) related to pDPN pain treatments, employment status, and productivity, as well as the following validated measures: the SF-12v2, one-week recall, the EQ-5D-3 L, the BPI-SF, the MOS Sleep Scale, the HADS, and the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) (customized to pDPN).

The participating physician or site coordinator conducted a 6-month retrospective chart review to collect time since pDPN diagnosis, duration of diabetes (underlying condition),...
number of comorbid conditions, pDPN-related treatments, and other pDPN-related health care resource utilization over the previous 6 months.

The BPI-SF includes four items measuring pain severity (at its worst, at its least, on average, and currently) and seven items measuring how pain interferes with activities of daily living and functioning (general activity, mood, walking ability, normal work, relationships with other people, sleep, and enjoyment of life). All items are assessed on 11-point numeric rating scales ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The BPI Pain Severity Index is calculated by taking the average of the worst, least, average, and current pain ratings. The BPI Pain Interference is calculated by averaging the mean of the seven interference items, with higher scores indicating greater interference with activities of daily living.

The HADS is designed to detect the presence and severity of anxiety or depression and has been used extensively in a variety of subject populations. The HADS includes 14 multiple-choice questions that are combined to form two subscales (anxiety and depression). Each subscale is based on the responses to seven questions. The overall score for each subscale ranges from 0 to 21, with higher scores representing poorer emotional well-being. Scores of 0–7 on either subscale represent “normal”, 8–10 represents “mild”, 11–14 represents “moderate”, and 15–21 represents “severe” levels of anxiety and depression.

The SF-12v2 (acute version: one-week recall) contains 12 items that assess eight domains, including physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. A physical and mental component score is also calculated. Higher scores on the SF-12 indicate better outcomes.

The EQ-5D-3 L is a general health status and utility measure that includes five items assessing subjects’ overall functioning and well-being with respect to mobility, self-care, performance of usual activities, pain or discomfort, and anxiety or depression. Subjects indicate their health state by selecting the most appropriate response (ie, no problems, some problems, or extreme problems) for each statement within each dimension. US health state valuation scores range from 0 to 100 and expressed as impairment percentages, with higher values indicating greater impairment and less productivity (ie, worse outcomes).

The WPAI-SHP is a six-item measure used to assess the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem quantitatively, and the specific health problem in this study was pDPN. Scores on the WPAI-SHP are multiplied by 100 and expressed as impairment percentages, with higher values indicating greater impairment and less productivity (ie, worse outcomes).

Direct medical costs to payers related to pDPN included health care provider visits for pDPN, including visits to physicians and nonphysician health care providers, prescription medications for pDPN, portable transcutaneous electrical nerve stimulation unit and supplies, office-based tests and procedures for pDPN, emergency room visits for pDPN, hospital outpatient visits for pDPN, and hospitalizations for pDPN. Direct costs to subjects (out-of-pocket costs) related to pDPN included medical care, child care, help with house and/or yard work, and help with activities of daily living. Indirect costs related to pDPN included overall work impairment, disability, unemployment, early retirement, and reduced work schedule.

Costing algorithms were developed to assign a “per unit” cost (2012 US$) to all health care resource utilization, excluding subject-reported out-of-pocket expenses, which were used as reported and did not need to be monetized. Unit costs for office visits, as well as office-based procedures and tests, were based on the fiscal year 2012 Medicare Physician Fee Schedule. Unit costs for hospital outpatient visits and emergency room visits were based again on the fiscal year 2012 Medicare Hospital Outpatient Prospective Payment System. Information on discharge diagnosis, procedures performed, and length of stay were used to map hospitalizations resulting in admission to appropriate Diagnosis Related Groups. Unit costs for hospitalizations were based on the fiscal year 2012 Medicare Hospital Inpatient Prospective Payment System. The 2012 Redbook was used to identify the unit cost of prescription generic and brand medications. To calculate the prescribed medication costs, the average wholesale price minus 18% plus a dispensing fee was used.

sleep adequacy, somnolence, and sleep quantity. In addition, nine of the 12 items also can be summarized into a nine-item overall index. With the exception of sleep quantity, the subscales and the nine-item Sleep Problems Index scores range from 0 to 100. The sleep quantity scale is the mean number of hours of sleep per night reported over the past week. Higher scores indicate worse outcomes for all domains except for Sleep Adequacy and Sleep Quantity scales, where higher scores indicate better outcomes.

The MOS Sleep Scale has been validated for use in patients with pDPN. This scale includes 12 questions that are combined to form six subscales measuring sleep disturbance, snoring, awakening short of breath or with a headache,
for brand medications, and average wholesale price minus 47% plus a dispensing fee was used for generic medications. For generics, the median price was selected if multiple price options were available for the strength indicated and bottle/package size needed. If the median price was between two options, the lower cost option was selected. Unit cost for use of a portable transcutaneous electrical nerve stimulation unit was based on the 2012 Medicare reimbursement schedule for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies.

The six-month and one-year cost of pDPN per subject was calculated and summarized as the direct medical cost to payers, direct costs to subjects, and indirect cost to society. In order to annualize direct medical costs to payers, the units of health care resource utilization used over the 6 months were multiplied by two (excluding transcutaneous electrical nerve stimulation units), and the annualized health care resource utilization was multiplied by the average cost per unit of the health care resource utilization. Direct out-of-pocket costs of pDPN to the subject were based on the 4-week data reported on the subject questionnaire. These costs were multiplied by 6.5 and 13 to calculate the 6-month (26-week) and annualized (52-week) costs of pDPN per subject, respectively.

Indirect costs associated with lost work-related productivity for those currently employed were calculated using the average hourly wage values obtained through the Bureau of Labor Statistics multiplied by the overall work impairment score from the WPAl:pDPN. Indirect costs to society as a result of lost productivity for subjects who were unemployed, retired early, or reduced their work schedule due to pDPN were calculated by multiplying the average hourly wage by time since change in employment status due to pDPN (up to 26 weeks for 6-month costs and up to 52 weeks for annualized costs). Indirect costs to society as a result of lost productivity for subjects disabled due to pDPN were calculated using the average hourly wage plus the average monthly disability payment from the Social Security Administration applied to the time since subjects were disabled due to pDPN.

Statistical analyses
Summary statistics (means and standard deviations [SD] for continuous variables and frequency distributions for categorical variables) were used to describe the sample. Scores on the BPI Pain Severity were used to classify average pain severity as follows: 0–3 represents mild pain, 4–6 represents moderate pain, and 7–10 represents severe pain. To evaluate the association between pain severity (categorized as mild, moderate, or severe) and other outcomes, we used Kruskal–Wallis for continuous outcomes and Chi-square or Fisher’s Exact tests for categorical outcomes. Statistical significance was evaluated at the 0.05 level.

The association between pain severity (mild, moderate, severe) and costs of neuropathic pain was examined using multiple (adjusted) linear regression. For the adjusted model, stepwise regression was used with the following pool of covariates: age, gender, race, ethnicity, pain severity, employment status (employed for pay/disabled/retired/unemployed/other), ability to walk, insurance coverage (yes/no), pDPN prescription coverage (yes/no), worker’s compensation, time since diagnosis, and comorbid conditions. All analyses were performed using PC-SAS version 9.1.3 (SAS Institute, Cary, NC).

Results
One hundred and twelve subjects with pDPN were enrolled in the study from 114 who were formally screened. Two potential subjects with pDPN failed screening, because they had more than one type of neuropathic pain.

Demographic and clinical characteristics
Table 1 presents the demographic and clinical characteristics of the sample overall and by pain severity. The mean age of the 112 subjects with pDPN enrolled in this cross-sectional, observational study was 61.1 ± 12.1 years overall (mild, 66.9 ± 10.78 years; moderate, 60.6 ± 12.25 years; severe, 57.8 ± 11.84; P = 0.0231, Table 1). There were 53 (47.3%) males and 59 (52.7%) females (Table 1). The mean pain severity score was 5.2 (0–10 scale) overall (mild 1.9 ± 1.19; moderate 5.0 ± 0.92; severe 7.8 ± 1.08), and subjects were distributed across pain severity levels as follows: 19.6% mild, 50.9% moderate, and 28.6% severe. One subject did not respond to all required items needed to calculate a mean BPI pain severity score, so the subject’s pain severity score is missing. Subjects had an average of 3.1 ± 2.2 comorbidities (Table 1). The most common conditions included sleep disturbance/insomnia (43.8%), depressive symptoms (41.1%), and anxiety (35.7%, Figure 1).

Ninety-one (81.3%) of the 112 subjects were diagnosed with diabetes more than 2 years prior to the date of consent, and another 15 (13.4%) were diagnosed with diabetes one year prior to the date of consent (Table 1). The overall mean time since pDPN diagnosis was 70.9 ± 65.3 months (Table 1), and the mean difference in time from first experiencing symptoms and diagnosis of pDPN was 17 months. On average, mean time since pDPN diagnosis was 81.8 ± 90.8, 68.5 ± 51.0, and 69.2 ± 69.3 months for subjects with mild,
Table 1 Demographic and clinical characteristics, overall and by average pain severity

| Characteristic                        | Overall (n = 112) | Mild (0–3) (n = 22) | Moderate (4–6) (n = 57) | Severe (7–10) (n = 32) | P value*
|--------------------------------------|------------------|---------------------|------------------------|-----------------------|---------
| Age, years                           | 61.1 ± 12.13     | 66.9 ± 10.78        | 60.6 ± 12.25           | 57.8 ± 11.84          | 0.0231  
| Gender, n (%)                        |                  |                     |                        |                       |         
| Male                                 | 53 (47.3)        | 14 (63.6)           | 28 (49.1)              | 10 (31.3)             | 0.0556  
| Race, n (%)                          |                  |                     |                        |                       |         
| American Indian or Alaska Native     | 2 (1.8)          | 0 (0.0)             | 1 (1.8)                | 1 (3.1)               | 0.10179 
| Asian                                | 2 (1.8)          | 0 (0.0)             | 1 (1.8)                | 1 (3.1)               |         
| Black or African American            | 15 (13.4)        | 1 (4.5)             | 6 (10.5)               | 8 (25.0)              |         
| Native Hawaiian or other Pacific Islander | 0 (0.0)    | 0 (0.0)             | 0 (0.0)                | 0 (0.0)               |         
| White                                | 77 (68.8)        | 19 (86.4)           | 42 (73.7)              | 15 (46.9)             |         
| Multiracial                          | 2 (1.8)          | 1 (4.5)             | 0 (0.0)                | 1 (3.1)               |         
| Other                                | 12 (10.7)        | 0 (0.0)             | 6 (10.5)               | 6 (18.8)              |         
| Education level, n (%)               |                  |                     |                        |                       | 0.0089  
| Missing                              | 3 (2.7)          | 0 (0.0)             | 1 (1.8)                | 2 (6.3)               |         
| Less than high school                | 22 (19.6)        | 0 (0.0)             | 12 (21.1)              | 9 (28.1)              |         
| High school and beyond               | 87 (77.7)        | 22 (100.0)          | 44 (77.2)              | 21 (65.6)             |         
| NoP prescription coverage, n (%)     |                  |                     |                        |                       | 0.5224  
| Missing                              | 2 (1.8)          | 1 (4.5)             | 1 (1.8)                | 0 (0.0)               |         
| No                                   | 9 (8.0)          | 2 (9.1)             | 6 (10.5)               | 1 (3.1)               |         
| Yes                                  | 101 (90.2)       | 19 (86.4)           | 50 (87.7)              | 31 (96.9)             |         
| Duration of diabetes, n (%)          |                  |                     |                        |                       | 0.3052  
| 6 months to 1 year                   | 6 (5.4)          | 3 (13.6)            | 2 (3.5)                | 1 (3.1)               |         
| 1 to 2 years                         | 15 (13.4)        | 4 (18.2)            | 6 (10.5)               | 5 (15.6)              |         
| 2+ years                             | 91 (81.3)        | 15 (68.2)           | 49 (86.0)              | 26 (81.3)             |         
| Time since pDPN diagnosis, months    | 70.9 ± 65.28     | 81.8 ± 90.82        | 68.5 ± 50.96           | 69.2 ± 69.31          | 0.9003  
| Number of comorbid conditions*       |                  |                     |                        |                       | 0.1441  
| Missing                              | 3.1 ± 2.18       | 2.2 ± 1.11          | 3.0 ± 2.21             | 3.8 ± 2.40            |         
| Employment status, n (%)             |                  |                     |                        |                       | 0.0605  
| Missing                              | 5 (4.5)          | 2 (9.1)             | 1 (1.8)                | 2 (6.3)               |         
| Employed for pay                     | 20 (17.9)        | 4 (18.2)            | 10 (17.5)              | 6 (18.8)              |         
| Disabled                             | 38 (33.9)        | 3 (13.6)            | 20 (35.1)              | 15 (46.9)             |         
| Retired                              | 41 (36.6)        | 13 (59.1)           | 21 (36.8)              | 6 (18.8)              |         
| Unemployed                           | 6 (5.4)          | 0 (0.0)             | 3 (5.3)                | 3 (9.4)               |         
| Other                                | 2 (1.8)          | 0 (0.0)             | 2 (3.5)                | 0 (0.0)               |         

Notes: *P values are from the Kruskal–Wallis test for continuous variables; the chi-square test for income level and health insurance; and the Fisher’s Exact test for the remaining categorical variables; mild versus moderate versus severe; *among subjects with at least one comorbid condition. One subject did not respond to all required items needed to calculate a BPI average pain severity score and thus was not included in any analysis by pain severity category.

Abbreviations: BPI, Brief Pain Inventory; SD, standard deviation; pDPN, painful diabetic peripheral neuropathy; NeP, neuropathic pain.

moderate, and severe pain severity scores, respectively (Table 1). Twenty (17.9%) of the 112 subjects reported being employed for pay (Table 1). Among those not employed for pay, most were either retired (36.6%) or disabled (33.9%, Table 1). Thirteen (11.6%) subjects reported being disabled due to their pDPN (data not shown).

Health-related quality of life
The mean Physical Component Summary and Mental Component Summary scores were 32.2 ± 10.1 and 44.0 ± 12.1, respectively (Figure 2A). Across all SF-12 domains, including both summary scores, higher pain severity was associated with lower health status (P < 0.0007, Table 2). Using the EQ-5D, the mean health utility score overall was 0.61 ± 0.22 (Table 2). Health utility scores also decreased significantly as pain severity increased (mild, 0.80 ± 0.13; moderate, 0.66 ± 0.17; and severe, 0.39 ± 0.18; P < 0.0001, Table 2).

The mean BPI-SF pain interference score was 5.0 ± 2.6, and mean scores increased significantly as pain severity increased (mild, 2.0 ± 1.8; moderate, 5.1 ± 1.9; and severe, 7.0 ± 1.9; P < 0.0001, Figure 2B). The mean MOS Sleep Overall Index score was 48.5 ± 19.6, and worsened significantly as pain severity increased (mild, 34.2 ± 15.0;
moderate, 48.7 ± 19.7; and severe, 58.5 ± 16.1; *P < 0.0001, Figure 2C). Scores on the HADS Anxiety and Depression scales indicate that over half (57.2%) of subjects with pDPN experienced some level of anxiety, and close to half (43.8%) experienced some level of depression (Table 2).

**Health resource use**

Ninety-one (81.3%) of the subjects were prescribed at least one medication for the treatment of pDPN (Figure 3A). As pain severity increased, the proportion of subjects prescribed one or more medications increased significantly (*P = 0.0004), with 96.9% of subjects in the severe pain group prescribed at least one prescription medication for pDPN. Overall, subjects were prescribed 1.6 ± 1.3 medications; across pain severity groups, the mean number of prescription medications per subject increased (mild 0.9 ± 1.0; moderate 1.5 ± 1.1; severe, 2.2 ± 1.4; *P = 0.0004, Table 3). The top four medication classes prescribed were antiepileptics (55.4%), weak short-acting opioids (17.0%), strong short-acting opioids (14.3%), and nonsteroidal anti-inflammatory
drugs (14.3% , Figure 3B). Among subjects prescribed antiepileptics, the most commonly prescribed medications were gabapentin (61.3%) and pregabalin (38.7%, data not shown). Among subjects prescribed weak short-acting opioids, all (100%) were prescribed hydrocodone-acetaminophen (data not shown). Among subjects prescribed strong short-acting opioids, the most commonly prescribed medications were oxycodone-acetaminophen (37.5%) and oxycodone hydrochloride immediate-release (31.3%, data not shown). Among subjects prescribed nonsteroidal anti-inflammatory drugs, the most commonly prescribed medications were ibuprofen (56.3%) and meloxicam (25.0%, data not shown). Thirteen (11.6%) subjects were prescribed a transcutaneous electrical nerve stimulation home device for neuropathic pain (data not shown).

In addition to prescription medications, 57 (50.9%) subjects reported taking nonprescription medications in the 4 weeks prior to enrolment; the top three most frequently used nonprescription medications in the pDPN cohort were ibuprofen (25.0%), vitamins (17.9%), and acetaminophen (12.5%, Table 4). Overall, subjects reported taking 0.9 ± 1.2 nonprescription medications over a 4-week period; across the pain severity groups, the mean number of nonprescription medications per subject increased (mild, 0.7 ± 0.9; moderate, 1.0 ± 1.4; severe, 0.9 ± 1.1) although the difference was not statistically significant (Table 3).

The mean number of pDPN-related physician office visits per subject in the 6 months prior to consent was 2.5 ± 1.9 (Table 3). The number of physician office visits increased as pain severity increased (mild, 1.7 ± 1.4; moderate, 2.4 ± 1.6; severe, 3.3 ± 2.3; P = 0.0171, Table 3). The mean number of pDPN-related other (nonphysician) health care provider visits per subject in the 6 months prior to consent of 0.1 ± 0.2 did not differ significantly by pain severity (Table 3). The mean number of office-based tests and procedures performed in the 6 months prior to consent was 0.8 ± 1.9, with fewer tests and procedures performed on subjects with more severe pain (mild, 1.0 ± 1.5; moderate, 0.8 ± 2.1; severe, 0.5 ± 1.8; P = 0.0143, Table 3). There was one pDPN-related emergency room visit in the 6 months prior to consent; no hospitalizations or hospital outpatient visits were reported (Table 3).

Lost productivity
Subjects reported on work and activity impairment due to their pDPN. Among subjects employed for pay (n = 20, 17.9%), mean overall work impairment was 43.6% (32.9%, Table 5). Across all subjects, mean overall activity impairment due to pDPN was 52.3% (31.1%, Table 5). Higher values indicate greater impairment in both domains. Activity impairment increased/worsened as pain severity increased (mild, 21.4% ± 21.9%; moderate, 52.5% ± 27.7%; severe, 74.8% ± 23.2%; P < 0.0001, Table 5).

Costs
Unadjusted mean annualized direct health care costs to the payer were $3302 ± $4611 per subject, and increased significantly as pain severity increased (mild, $1624 ± $2021; moderate, $3353 ± $4606; severe, $4464 ± $5595; P = 0.0134, data not shown). Annualized prescription medication costs were the primary driver of the total direct costs to the payer, making up, on average, 86.8% of the total unadjusted mean annualized direct costs to the payer, followed by physician office visits (10.7%, data not shown). Unadjusted mean annualized direct costs to subjects (out-of-pocket costs) were $1352 ± $2627 overall ($1075 ± $1386 for mild; $1346 ± $3181 for moderate; and $1587 ± $2233 for severe pain subgroups; P = 0.8037, data not shown). Unadjusted total mean annualized direct health care costs were $4654 ± $5605, and increased significantly as pain severity increased (mild, $2699 ± $2827; moderate, $4699 ± $6047; severe, $6051 ± $5976; P = 0.0267, data not shown).

Unadjusted total mean annualized indirect costs per subject were $9632 ± $19,108 overall ($1595 ± $4514 for mild; $9007 ± $17,980 for moderate; and $16,574 ± $24,702 for severe pain subgroups; P = 0.1131, data not shown).

The total mean annualized adjusted direct health care costs per subject were $4841 and total mean annualized adjusted indirect costs per subject were $9730 (Figure 4). Across pain severity levels, differences in annualized...
Table 2 Subject-reported outcomes, overall and by average pain severity

| Scale                          | Overall (n = 112) | Mild (0–3) (n = 22) | Moderate (4–6) (n = 57) | Severe (7–10) (n = 32) | P value* |
|-------------------------------|-------------------|---------------------|-------------------------|------------------------|----------|
| SF-12a                        |                   |                     |                         |                        |          |
| Physical functioning          |                   |                     |                         |                        |          |
| Mean (SD)                     | 33.3 ± 32.60      | 58.0 ± 35.68        | 31.1 ± 30.72            | 21.1 ± 24.68           | 0.0006   |
| Median                        | 25.0              | 50.0                | 25.0                    | 25.0                   |          |
| Range                         | 0–100             | 0–100               | 0–100                   | 0–100                  |          |
| Role physical                 |                   |                     |                         |                        | 0.0001   |
| Mean (SD)                     | 39.4 ± 28.53      | 62.5 ± 32.50        | 37.7 ± 23.08            | 27.3 ± 26.07           |          |
| Median                        | 37.5              | 62.5                | 37.5                    | 25.0                   |          |
| Range                         | 0–100             | 0–100               | 0–100                   | 0–100                  |          |
| Bodily pain                   |                   |                     |                         |                        | <0.0001  |
| Mean (SD)                     | 40.2 ± 28.35      | 70.5 ± 26.32        | 39.5 ± 23.12            | 21.1 ± 20.19           |          |
| Median                        | 25.0              | 75.0                | 25.0                    | 25.0                   |          |
| Range                         | 0–100             | 25–100              | 0–100                   | 0–75                   |          |
| General health                |                   |                     |                         |                        | <0.0001  |
| Mean (SD)                     | 35.9 ± 24.56      | 61.6 ± 24.12        | 32.2 ± 20.44            | 25.3 ± 19.96           |          |
| Median                        | 25.0              | 60.0                | 25.0                    | 25.0                   |          |
| Range                         | 0–85              | 0–85                | 0–85                    | 0–60                   |          |
| Vitality                      |                   |                     |                         |                        | 0.0002   |
| Mean (SD)                     | 33.5 ± 26.11      | 51.1 ± 22.46        | 32.0 ± 23.51            | 23.4 ± 27.63           |          |
| Median                        | 25.0              | 50.0                | 25.0                    | 25.0                   |          |
| Range                         | 0–100             | 0–75                | 0–75                    | 0–100                  |          |
| Social functioning            |                   |                     |                         |                        | 0.0003   |
| Mean (SD)                     | 56.5 ± 32.49      | 73.9 ± 26.14        | 60.1 ± 30.93            | 38.3 ± 31.74           |          |
| Median                        | 50.0              | 75.0                | 50.0                    | 25.0                   |          |
| Range                         | 0–100             | 25–100              | 0–100                   | 0–100                  |          |
| Role emotional                |                   |                     |                         |                        | <0.0001  |
| Mean (SD)                     | 58.4 ± 31.09      | 80.7 ± 23.38        | 62.5 ± 28.35            | 35.2 ± 26.27           |          |
| Median                        | 50.0              | 87.5                | 62.5                    | 25.0                   |          |
| Range                         | 0–100             | 13–100              | 0–100                   | 0–100                  |          |
| Mental health                 |                   |                     |                         |                        | <0.0001  |
| Mean (SD)                     | 58.5 ± 23.32      | 72.7 ± 19.15        | 62.3 ± 21.32            | 41.4 ± 19.94           |          |
| Median                        | 62.5              | 81.3                | 62.5                    | 50.0                   |          |
| Range                         | 0–100             | 25–100              | 13–100                  | 0–88                   |          |
| EQ-5Da                        |                   |                     |                         |                        |          |
| Health state utility          |                   |                     |                         |                        | <0.0001  |
| Mean (SD)                     | 0.61 ± 0.22       | 0.80 ± 0.13         | 0.66 ± 0.17             | 0.39 ± 0.18            |          |
| Median                        | 0.7               | 0.8                 | 0.7                     | 0.4                    |          |
| Range                         | 0.2–1.0           | 0.4–1.0             | 0.2–0.8                 | 0.2–0.8                |          |
| HADS                          |                   |                     |                         |                        | 0.0026   |
| HADS Anxiety, n (%)           |                   |                     |                         |                        |          |
| Normal (0–7)                  | 48 (42.9)         | 16 (72.7)           | 25 (43.9)               | 7 (21.9)               |          |
| Mild (7–10)                   | 40 (35.7)         | 6 (27.3)            | 20 (35.1)               | 13 (40.6)              |          |
| Moderate (11–14)              | 20 (17.9)         | 0 (0.0)             | 11 (19.3)               | 9 (28.1)               |          |
| Severe (15–21)                | 4 (3.6)           | 0 (0.0)             | 1 (1.8)                 | 3 (9.4)                |          |
| HADS Depression, n (%)        |                   |                     |                         |                        | 0.0030   |
| Normal (0–7)                  | 63 (56.3)         | 18 (81.8)           | 33 (57.9)               | 12 (37.5)              |          |
| Mild (7–10)                   | 21 (18.8)         | 4 (18.2)            | 12 (21.1)               | 4 (12.5)               |          |
| Moderate (11–14)              | 19 (17.0)         | 0 (0.0)             | 8 (14.0)                | 11 (34.4)              |          |
| Severe (15–21)                | 9 (8.0)           | 0 (0.0)             | 4 (7.0)                 | 5 (15.6)               |          |

Notes: *P values are from the Kruskal–Wallis test for continuous variables; mild versus moderate versus severe. P values are from the Fisher’s Exact test for categorical variables; mild versus moderate versus severe. Higher scores indicate a better subject-reported outcome.

Abbreviations: SD, standard deviation; EQ-5D, EuroQol 5-dimensions; HADS, Hamilton Anxiety and Depression Scale; SF-12, 12-Item Short-Form Health Survey; NeP, neuropathic pain.
adjusted direct (P < 0.0001) and indirect (P = 0.0003) costs were significant (Figure 4).

**Discussion**

This is one of the few studies that attempted to evaluate comprehensively the overall burden of illness (ie, patient-reported outcomes, health care resource utilization, lost productivity, and cost) among adults in the US with pDPN. Subjects in this study were required to have a diagnosis of pDPN for at least 6 months and were actively seeking care (presented at routine office visits). The current study sample is consistent with samples in other published studies in the US and Europe, with regards to age, gender, race, proportion of subjects employed, and high proportion of subjects with moderate or severe pain.1,5,10,31

In comparison with US normative data on the MOS Overall Sleep Index of 25.8,16 patients with pDPNs in this

---

**Figure 3A** Proportion of pDPN subjects taking prescription medications for pDPN, overall and by average pain severity.8

**Notes:** 8Scores on the BPI Pain Severity were used to classify average pain severity as follows: 0–3 represents mild pain, 4–6 represents moderate pain, and 7–10 represents severe pain; 9proportion of pDPN subjects taking prescription medications for their pDPN significantly different by pain severity (P = 0.0004).

**Figure 3B** Use of prescription treatments for pDPN, overall.

**Notes:** 8Subjects may be taking more than one class of prescription medication; 9Weak SOA, Strong SOA, and LAO were also collapsed into “All Opioids” class; proportion prescribed = 33.0% overall, 9.1% mild, 31.6% moderate, 53.1% severe (P = 0.0027).

**Abbreviations:** AEDs, antiepileptics; SOA, strong-acting opioids; NSAIDs, nonsteroidal anti-inflammatory drugs; LAO, long-acting opioids; SNRIs, Serotonin–norepinephrine reuptake inhibitors; TCAs, tricyclic antidepressants; SSRI, selective serotonin re-uptake inhibitors.
Table 3 Resource utilization for painful diabetic peripheral neuropathy, overall and by average pain severity

| Resource use                                      | Overall (n = 112) | Mild (0–3) (n = 22) | Moderate (4–6) (n = 57) | Severe (7–10) (n = 32) | P value* |
|--------------------------------------------------|-------------------|---------------------|-------------------------|------------------------|----------|
| Medication                                        |                   |                     |                         |                        |          |
| Prescription medications prescribed to subject, mean (SD) | 1.6 ± 1.25        | 0.9 ± 1.04          | 1.5 ± 1.10              | 2.2 ± 1.37             | 0.0004   |
| Nonprescription medications used, mean (SD)       | 0.9 ± 1.24        | 0.7 ± 0.89          | 1.0 ± 1.41              | 0.9 ± 1.13             | 0.7325   |
| Office visit                                      |                   |                     |                         |                        |          |
| Physician office visits for NeP, mean (SD)        | 2.5 ± 1.86        | 1.7 ± 1.35          | 2.4 ± 1.59              | 3.3 ± 2.31             | 0.0171   |
| Nonphysician office visits for NeP over the past 6 months, mean (SD) | 0.1 ± 0.23        | 0.1 ± 0.29          | 0.1 ± 0.26              | 0.0 ± 0.00             | 0.2621   |
| Test and procedure                                |                   |                     |                         |                        |          |
| Outpatient tests or procedures, mean (SD)         | 0.8 ± 1.92        | 1.0 ± 1.46          | 0.8 ± 2.13              | 0.5 ± 1.83             | 0.0143   |
| ER visits for NeP, mean (SD)                      | 0.0 ± 0.09        | 0.0 ± 0.00          | 0.0 ± 0.00              | 0.0 ± 0.18             | 0.2910   |
| Hospital outpatient visits for NeP, mean (SD)     | 0.0 ± 0.00        | 0.0 ± 0.00          | 0.0 ± 0.00              | 0.0 ± 0.00             | 1.0000   |
| Hospitalizations for NeP, mean (SD)               | 0.0 ± 0.00        | 0.0 ± 0.00          | 0.0 ± 0.00              | 0.0 ± 0.00             | 1.0000   |

Notes: *P values are from the Kruskal–Wallis test for continuous variables and Fisher’s Exact test for categorical variables; mild versus moderate versus severe; over the past 6 months; over the past 4 weeks. One subject did not respond to all required items needed to calculate a BPI average pain severity score and thus was not included in any analysis by pain severity category.

Abbreviations: SD, standard deviation; ER, emergency room; NeP, neuropathic pain; BPI, Brief Pain Inventory.

Table 4 Subject-reported nonprescription medications used to treat painful diabetic peripheral neuropathy, overall and by average pain severity

| Characteristic                                      | Overall (n = 112) | Mild (0–3) (n = 22) | Moderate (4–6) (n = 57) | Severe (7–10) (n = 32) | P value* |
|-----------------------------------------------------|-------------------|---------------------|-------------------------|------------------------|----------|
| Nonprescription medication used in past 4 weeks n (%) | 0.8217            |                     |                         |                        |          |
| Missing                                             | 0 (0.0)           | 0 (0.0)             | 0 (0.0)                 | 0 (0.0)                |          |
| No                                                  | 55 (49.1)         | 12 (54.5)           | 27 (47.4)               | 16 (50.0)              |          |
| Yes                                                 | 57 (50.9)         | 10 (45.5)           | 30 (52.6)               | 16 (50.0)              |          |
| Nonprescription treatment used                       |                   |                     |                         |                        |          |
| Aspirin, n (%)                                      | 13 (11.6)         | 1 (4.5)             | 8 (14.0)                | 4 (12.5)               | 0.6942   |
| Acetaminophen, n (%)                                | 14 (12.5)         | 2 (9.1)             | 11 (19.3)               | 1 (3.1)                | 0.0869   |
| Ibuprofen, n (%)                                    | 28 (25.0)         | 7 (31.8)            | 13 (22.8)               | 7 (21.9)               | 0.3053   |
| Naproxen, n (%)                                     | 9 (8.0)           | 1 (4.5)             | 3 (5.3)                 | 5 (15.6)               | 0.1571   |
| Herbs, n (%)                                        | 5 (4.5)           | 0 (0.0)             | 3 (5.3)                 | 2 (6.3)                | 0.8268   |
| Vitamins, n (%)                                     | 20 (17.9)         | 2 (9.1)             | 13 (22.8)               | 5 (15.6)               | 0.5278   |
| Supplements, n (%)                                  | 9 (8.0)           | 1 (4.5)             | 4 (7.0)                 | 4 (12.5)               | 0.6048   |
| Other, n (%)                                        | 7 (6.3)           | 1 (4.5)             | 4 (7.0)                 | 2 (6.3)                | 1.0000   |

Notes: *P values are from the Kruskal–Wallis test for continuous variables and the Fisher’s Exact test for categorical variables; mild versus moderate versus severe; two subjects who reported using a specific nonprescription medication were assumed to have answered “yes” to the question: “Have you taken any nonprescription (over-the-counter) medications (including pills, tablets, capsules, and/or topical lotions or creams), herbs, vitamins, and/or other supplements in the past 4 weeks for your neuropathic pain?”; because more than one response may be selected, the sum of percentages across response options may exceed 100. Mild, moderate, and severe classification was based on the average BPI pain severity score. One subject did not respond to all required items needed to calculate an average BPI pain severity score and thus was not included in any analysis by pain severity category.

Abbreviation: BPI, Brief Pain Inventory.
### Table 5 Work productivity and activity impairment: pDPN (WPAI:pDPN), overall and by average pain severity

| Productivity | Overall (n = 112) | Mild (0–3) (n = 22) | Moderate (4–6) (n = 57) | Severe (7–10) (n = 32) | P value* |
|--------------|-------------------|---------------------|-------------------------|------------------------|---------|
| Employed for pay, n (%) | 20 (17.9) | 4 (18.2) | 10 (17.5) | 6 (18.8) | 1.0000 |
| Overall work impairmentb | 19 | 3 | 10 | 6 | 0.1721 |
| n | 43.6 ± 32.9 | 23.3 ± 5.8 | 36.4 ± 31.3 | 65.6 ± 34.6 | |
| Median | 30.0 | 20.0 | 30.0 | 75.0 | |
| Range | 0–100 | 0–30 | 0–100 | 0–100 | |
| Activity impairmentc | 111 | 22 | 57 | 31 | <0.0001 |
| n | 52.3 ± 31.1 | 21.4 ± 21.9 | 52.5 ± 27.7 | 74.8 ± 23.2 | |
| Median | 60.0 | 15.0 | 60.0 | 80.0 | |
| Range | 0–100 | 0–70 | 0–100 | 0–100 | |

**Notes:** *P values are from the Kruskal–Wallis test for continuous variables and the Fisher’s Exact test for categorical variables; mild versus moderate versus severe; *higher values indicate greater impairment; †among those employed for pay. One subject did not respond to all required items needed to calculate a BPI average pain severity score and thus was not included in any analysis by pain severity category.

**Abbreviations:** BPI, Brief Pain Inventory; SD, standard deviation; dDPN, painful diabetic peripheral neuropathy; WPAI, Work Productivity and Activity Impairment.

---

decreased as pain severity increased using both the SF-12 and EQ-5D. Although subjects were actively managed, the results support the finding that subjects with pDPN experienced substantially lower health status than the general US population, as reflected by scores on the Mental Component Summary (44.0), Physical Component Summary (32.2), and EQ-5D utilities (0.61), compared with the US norms of 49.48 (Mental Component Summary), 49.70 (Physical Component Summary), and 0.87 (EQ-5D utility). This study also found an association between mean utilities and pain severity (mild 0.80; moderate 0.66; and severe 0.39; \( P < 0.0001 \)). Toelle et al similarly reported a substantial decrement in health status among subjects with pDPN measured by EQ-5D health state valuations (0.59, 0.43, and 0.20 for mild, moderate, and severe pain, respectively; \( P < 0.001 \)). The subjects with pDPN in the current study were comparable with those included in the study by Tolle et al with regards to duration of pDPN, pain severity, and health status. In order for physicians to create a tailored pDPN management strategy, an evaluation of depression, anxiety, and sleep, as well as the impact of pDPN on other measures of health status, is needed prior to and following initiation of treatment.

A comprehensive evaluation of the direct and indirect costs of pDPN, overall and by severity level, from a US patient-centered perspective, was conducted. Health care resource use, specifically the number of pDPN-related prescription medications (mild 0.9; moderate 1.5; severe 2.2; \( P = 0.0004 \)),

---

**Figure 4** Adjusted average annualized cost per pDPN subject, overall and by average pain severity.

**Notes:** *Scores on the BPI Pain Severity were used to classify average pain severity as follows: 0–3 represents mild pain, 4–6 represents moderate pain, and 7–10 represents severe pain; †average annualized total direct cost per pDPN subject was significantly different by pain severity (\( P < 0.0001 \)). Direct costs include physician visits, other healthcare provider visits, prescription medications, TENS device, outpatient tests/procedures, emergency room visits, hospital outpatient visits, hospitalizations, direct medical costs to subjects, and direct non-medical (child care, help with house and/or yard work, and help with activities of daily living) due to pDPN; ‡average annualized total indirect cost per pDPN subject was significantly different by pain severity (\( P = 0.0003 \)). Total indirect costs include overall work impairment, activity impairment, disability, unemployment, early retirement, and reduced work schedule due to pDPN; †adjusted LS mean estimates from multiple linear regression adjusted for confounding demographic and clinical variables. Covariates included in adjusting direct costs: race, pain severity (mild/moderate/severe only), employment status, worker’s compensation, and comorbidities (depressive symptoms, headache/migraine, fibromyalgia [mild/moderate/severe only], chronic fatigue syndrome [overall only], and chronic low back pain); covariates included in adjusting indirect costs: sex, race, pain severity, employment status, worker’s compensation, and comorbidities (major depressive disorder and Raynaud’s syndrome).
as well as the number of office visits per subject (mild 1.7; moderate 2.4; severe 3.3; \( P = 0.0171 \)), increased as neuropathic pain severity level increased. A similar trend of increased health care resource utilization among those with greater pain severity has been shown in previous studies of pDPN with comparable pDPN samples (specifically age, gender, race, employment status, duration of pDPN, and pain severity).\(^8,10\) Gore et al estimated that approximately 60% of patients with pDPN had had at least two health care provider visits over the preceding 3 months and that subjects had averaged 3.8 prescription medications and 2.1 nonprescription medications in the previous week.\(^8\) Our study found an average of 2.5 physician office visits and 1.6 prescription medications in the past 6 months for the management of pDPN, and 0.9 pDPN nonprescription medications in the past 4 weeks. Although DiBonaventura et al reported a similar trend of higher health care resource utilization among those with greater pain severity, they reported more health care provider visits, hospitalizations, and emergency room visits per subject.\(^10\) It is important to note that DiBonaventura et al reported all-cause health care resource utilization and relied on patient self-reporting via the National Health and Wellness Survey.

High health care resource utilization rates resulted in substantial total direct medical costs per patient. This study demonstrated that costs increased as pain severity increased. The major drivers of the direct medical costs in our study were prescription medications (86.8% of mean annualized direct medical costs) and physician office visits (10.7% of mean annualized direct medical costs). Two US studies that reported costs did not collect data on medication use; both reported that hospitalizations were the primary driver of direct costs. Ritzwoller et al reported more than half of the total annual direct costs for subjects with pDPN were due to inpatient stays.\(^12\) Ritzwoller et al used medical claims to assess resource use; resource use identified through medical claims databases cannot be attributed directly to pDPN. The pDPN sample analyzed by Ritzwoller et al was slightly older but had a gender distribution similar to that in the current study. DiBonaventura et al reported mean annual direct costs ($5786 among mild, $7762 among moderate, and $12,856 among severe). The primary drivers of the direct costs were hospitalizations ($2725) and provider visits ($2389). Direct costs were higher among those with greater pain.\(^10\) Although the estimated direct costs reported by DiBonaventura et al are greater than in the current study, it is important to note that these reflect all-cause health care resource utilization, while the current study reports costs specific to pDPN. The current study also collected data on subjects’ out-of-pocket costs.

Indirect costs due to lost productivity, as well as indirect costs due to changes in employment status due to pDPN, were calculated, making the assessment of indirect costs more comprehensive than that in the current published literature. DiBonaventura et al reported total annual indirect costs due to lost productivity of $3641, $3413, and $3927 among mild, moderate, and severe pain groups, respectively.\(^10\) The findings of the current study suggest that changes in employment status as well as lost productivity have a substantial impact on total costs. WPAI scores also showed a significant increase in activity impairment with increasing pain severity, thus establishing a clear relationship between pain and activities of daily living in this patient population. The results of this study point to the potential economic benefits of more effective management of pDPN.

**Limitations**

There are several limitations inherent in this analysis, particularly related to the possibility of incurring selection bias. First, this study enrolled subjects actively seeking medical care for their pDPN, as they presented for a routine medical appointment. Further, this study enrolled subjects diagnosed with pDPN at least 6 months earlier who had been managed at the physician’s practice for at least 6 months. As such, these findings may not be generalizable to others with pDPN who are not seeking treatment, or do not regularly visit their physician. However, in comparing standard demographic and clinical characteristics, including age, gender, race, employment status, duration of pDPN, pain severity, sleep outcomes, and anxiety and depression, the current study sample appears consistent with samples in previously published studies, which used alternative sampling methods.

This cross-sectional study required a retrospective review of medical records, which could lead to overreporting or underreporting of health care resource utilization. The subject’s medical record may not include all visits to other physicians, health care providers, facilities, and pDPN-related tests and procedures conducted, and medications prescribed outside of the study site. However, physicians and site coordinators were asked to review the health care resource utilization with subjects during their appointment. Similarly, data captured in this study was based on the physician and/or study site coordinator’s assessment of health care resource utilization attributable to pDPN versus the underlying condition, ie, diabetes. Therefore, it may have been difficult to separate out neuropathic pain-related health care resource utilization from that due to diabetes.
Direct costs were assigned using a standard algorithm. Actual costs to the payer may be higher or lower. Similarly, costs were assigned to indirect costs based on average wage data, which may have overestimated or underestimated these costs. Finally, indirect costs and out-of-pocket costs were based on subject recall, so may have resulted in overestimation or underestimation of annualized costs.

**Conclusion**

In summary, subjects with pDPN in this study reported moderate and severe levels of pain, on average, and suboptimal levels of overall health, functioning, and well-being despite receiving active management. Further, the economic burden of pDPN was increased when pain severity was greater. These findings highlight the importance and value of effective pain management in subgroups of subjects with pDPN.

**Disclosure**

This research was supported by Pfizer Inc. AS and BP are paid employees of Pfizer Inc. RB, FB, RM, and CS are employees of Covance Market Access Services Inc, who were paid consultants to Pfizer Inc in the development and execution of this study and manuscript. AA and SN were paid investigators for the study. BS, EN, and MT were not financially compensated for their collaborative efforts on this project, including publication-related activities.

**References**

1. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai K-S, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. *J Pain Symptom Manage*. 2005;30(4):374–385.
2. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A Review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. *Pain Practice*. 2008;8(1):45–56.
3. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population >40 years of age with and without diabetes: 1999–2000 national health and nutrition examination survey. *Diabetes Care*. 2004;27:1591–1597.
4. Galluzzi KE. Management of neuropathic pain. *J Am Osteopath Assoc*. 2005;105 Suppl 4:S12–S19.
5. Taylor-Stokes G, Patel J, Sadosky A, Chandran A, Toelle T. Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy. *Diabetes Metab Syndr Obes*. 2011;4:401–408.
6. Baron R, Tölle TR, Gockel U, Bross M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. *Pain*. 2009;146(1):34–40.
7. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. *J Diabetes Complications*. 2006;20(1):26–33.
8. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. *J Pain*. 2006;7(12):892–900.
9. Jensen MP, Chodoff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life. *Neurology*. 2007;68(15):1178–1182.
10. daCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. *Pain Med*. 2011;12(1):118–126.
11. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Health care utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy. *J Am Geriatr Soc*. 2011;59(5):827–836.
12. Ritzowler DP, Ellis JL, Korner EJ, Hartsfield CL, Sadosky A. Comorbidities, health care service utilization and costs for patients identified with painful DPN in a managed-care setting. *Curr Med Res Opin*. 2009;25(6):1319–1328.
13. Ware JE, Kosinski M, Turner-Bowker DM, Sundaram M, Gandek B, Maruish ME. User’s Manual for the SF-12v2 Health Survey Second Edition: Lincoln, RI: QualityMetric Incorporated; 2009.
14. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. *Ann Med*. 2001;33(5):337–343.
15. Cleeeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singapore*. 1994;23(2):129–138.
16. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. *Sleep Med*. 2005;6(1):41–44.
17. Snith RP, Zignmond AS. The Hospital Anxiety and Depression scale. *Br Med J (Clin Res Ed)*. 1986;292(6516):344–349.
18. Zignmond AS, Snith RP. The Hospital Anxiety And Depression scale. *Acta Psychiatr Scand*. 1983;67(6):361–370.
19. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmaco economics*. 1993;4(5):353–365.
20. Cleeeland C. The Brief Pain Inventory User Guide. 2009. Available from: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf. Accessed September 15, 2011.
21. Reilly Associates. WPAI Scoring. Available from: http://www.reillyassociates.net/WPAI_Scoring.html. Accessed December 10, 2012.
22. Pharmacy Benefit Management Institute. Pharmacy and drug manufacturer reimbursement. Available from: http://www.benefitdesignreport.com/PharmacyReimbursement/tabid/66/Default.aspx. Accessed November 26, 2012.
23. US Department of Labor. Bureau of Labor Statistics. Available from: http://www.bls.gov/oes/current/oes_nat.htm#00-0000. Accessed November 26, 2012.
24. Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. *Pharmaco economics*. 2004;22(3):165–184.
25. Social Security Administration. Research, Statistics and Policy Analysis. Available from: http://www.ssa.gov/policy/docs/quickfacts/stat_snaphot/. Accessed November 26, 2012.
26. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Classification of mild, moderate and severe pain due to diabetic peripheral neuropathy based on levels of functional disability. *J Pain*. 2004;5 Suppl 1:114.
27. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. *Pain*. 2005;115(1–2):29–36.
30. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. *Eur J Pain*. 2006;10(2):127–135.
31. O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. *Pharmacoeconomics*. 2009;27(2):95–112.
32. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. *Clin J Pain*. 2006;22(8):681–685.
33. Ware JE, Kosinski M, Turner-Bowker DM, Sundaram M, Gandek B, Maruish ME. User’s Manual for the SF-12v2 Health Survey Second Edition. Lincoln, RI: QualityMetric Incorporated; 2009.
34. Luo N JJ, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult US population as assessed by the EQ-5D and Health Utilities Index. *Med Care*. 2005;43(11):1078–1086.
35. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. *Eur J Neurol*. 2004;11(3):153–162.